These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 2252453)

  • 1. Effects of physostigmine on spatial attention in patients with progressive supranuclear palsy.
    Kertzman C; Robinson DL; Litvan I
    Arch Neurol; 1990 Dec; 47(12):1346-50. PubMed ID: 2252453
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Frontal lobe function in progressive supranuclear palsy.
    Grafman J; Litvan I; Gomez C; Chase TN
    Arch Neurol; 1990 May; 47(5):553-8. PubMed ID: 2334303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological evaluation of the cholinergic system in progressive supranuclear palsy.
    Litvan I; Blesa R; Clark K; Nichelli P; Atack JR; Mouradian MM; Grafman J; Chase TN
    Ann Neurol; 1994 Jul; 36(1):55-61. PubMed ID: 8024262
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Physostigmine treatment of progressive supranuclear palsy.
    Litvan I; Gomez C; Atack JR; Gillespie M; Kask AM; Mouradian MM; Chase TN
    Ann Neurol; 1989 Sep; 26(3):404-7. PubMed ID: 2802540
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ERP evidence for selective drop in attentional costs in uncertain environments: challenging a purely premotor account of covert orienting of attention.
    Lasaponara S; Chica AB; Lecce F; Lupianez J; Doricchi F
    Neuropsychologia; 2011 Jul; 49(9):2648-57. PubMed ID: 21640737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of the cholinergic agonist nicotine on reorienting of visual spatial attention and top-down attentional control.
    Thiel CM; Fink GR
    Neuroscience; 2008 Mar; 152(2):381-90. PubMed ID: 18272290
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does the enhancement of cholinergic neurotransmission influence brain glucose kinetics and clinical symptomatology in progressive supranuclear palsy?
    Blin J; Mazetti P; Mazoyer B; Rivaud S; Ben Ayed S; Malapani C; Pillon B; Agid Y
    Brain; 1995 Dec; 118 ( Pt 6)():1485-95. PubMed ID: 8595479
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Moderation of nicotine effects on covert orienting of attention tasks by poor placebo performance and cue validity.
    Hammersley JJ; Gilbert DG; Rzetelny A; Rabinovich NE
    Pharmacol Biochem Behav; 2016 Oct; 149():9-16. PubMed ID: 27461547
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cholinergic approaches to the treatment of progressive supranuclear palsy.
    Litvan I
    J Neural Transm Suppl; 1994; 42():275-81. PubMed ID: 7964692
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Orienting of visual attention in progressive supranuclear palsy.
    Rafal RD; Posner MI; Friedman JH; Inhoff AW; Bernstein E
    Brain; 1988 Apr; 111 ( Pt 2)():267-80. PubMed ID: 3378136
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Covert orienting of attention in macaques. I. Effects of behavioral context.
    Bowman EM; Brown VJ; Kertzman C; Schwarz U; Robinson DL
    J Neurophysiol; 1993 Jul; 70(1):431-43. PubMed ID: 8360720
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of physostigmine on swallowing and oral motor functions in patients with progressive supranuclear palsy: A pilot study.
    Frattali CM; Sonies BC; Chi-Fishman G; Litvan I
    Dysphagia; 1999; 14(3):165-8. PubMed ID: 10341115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nicotine modulates reorienting of visuospatial attention and neural activity in human parietal cortex.
    Thiel CM; Zilles K; Fink GR
    Neuropsychopharmacology; 2005 Apr; 30(4):810-20. PubMed ID: 15668726
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuropsychological performance, disease severity, and depression in progressive supranuclear palsy.
    Esmonde T; Giles E; Gibson M; Hodges JR
    J Neurol; 1996 Sep; 243(9):638-43. PubMed ID: 8892064
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The pattern of verbal, visuospatial and procedural learning in Richardson variant of progressive supranuclear palsy in comparison to Parkinson's disease.
    Sitek EJ; Wieczorek D; Konkel A; Dąbrowska M; Sławek J
    Psychiatr Pol; 2017 Aug; 51(4):647-659. PubMed ID: 28987055
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The applause sign and neuropsychological profile in progressive supranuclear palsy and Parkinson's disease.
    Somme J; Gómez-Esteban JC; Tijero B; Berganzo K; Lezcano E; Zarranz JJ
    Clin Neurol Neurosurg; 2013 Aug; 115(8):1230-3. PubMed ID: 23253819
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Asymmetries in the covert orienting of visual spatial attention to spatial and non-spatial cues in Alzheimer's disease.
    Maruff P; Malone V; Currie J
    Brain; 1995 Dec; 118 ( Pt 6)():1421-35. PubMed ID: 8595474
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Frontal deficits differentiate progressive supranuclear palsy from Parkinson's disease.
    Lee YE; Williams DR; Anderson JF
    J Neuropsychol; 2016 Mar; 10(1):1-14. PubMed ID: 25223526
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Covert orienting of attention in macaques. II. Contributions of parietal cortex.
    Robinson DL; Bowman EM; Kertzman C
    J Neurophysiol; 1995 Aug; 74(2):698-712. PubMed ID: 7472375
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic influences on cognition in progressive supranuclear palsy.
    Gerstenecker A; Roberson ED; Schellenberg GD; Standaert DG; Shprecher DR; Kluger BM; Litvan I
    Mov Disord; 2017 Dec; 32(12):1764-1771. PubMed ID: 29076559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.